Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
Covington
Fuji
Chinese Patent Office
Cerilliant
Teva
Chubb
QuintilesIMS

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VINCASAR PFS

« Back to Dashboard

Clinical Trials for Vincasar Pfs

Trial ID Title Status Sponsor Phase Summary
NCT00390793 Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL Active, not recruiting Bristol-Myers Squibb Phase 2 The goal of this clinical research study is to find out if intensive chemotherapy combined with dasatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied.
NCT00390793 Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL Active, not recruiting M.D. Anderson Cancer Center Phase 2 The goal of this clinical research study is to find out if intensive chemotherapy combined with dasatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied.
NCT02043587 Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Recruiting Sigma Tau Pharmaceuticals, Inc. Phase 2 The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.
NCT02043587 Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Recruiting University of California, San Diego Phase 2 The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.
NCT02660762 Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL Recruiting Sun Yat-sen University Phase 2 This prospective study was conducted to evaluate the efficacy and safety profiles of Modified MRCUKALLⅫ/ECOGE2993 Regimen in young adults with newly diagnosed, low-risk, Philadelphia chromosome negative acute lymphoblastic leukaemia.
NCT03007147 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Not yet recruiting National Cancer Institute (NCI) Phase 3 This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Vincasar Pfs

Condition Name

Condition Name for Vincasar Pfs
Intervention Trials
CD20 Positive 2
Adult Lymphoblastic Lymphoma 2
B-Cell Non-Hodgkin Lymphoma 2
Philadelphia Chromosome Positive 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vincasar Pfs
Intervention Trials
Lymphoma 5
Precursor Cell Lymphoblastic Leukemia-Lymphoma 5
Leukemia 5
Lymphoma, Non-Hodgkin 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vincasar Pfs

Trials by Country

Trials by Country for Vincasar Pfs
Location Trials
United States 37
Tanzania 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vincasar Pfs
Location Trials
Pennsylvania 3
Texas 2
Illinois 2
North Carolina 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vincasar Pfs

Clinical Trial Phase

Clinical Trial Phase for Vincasar Pfs
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 1
Phase 2 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vincasar Pfs
Clinical Trial Phase Trials
Recruiting 6
Not yet recruiting 4
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vincasar Pfs

Sponsor Name

Sponsor Name for Vincasar Pfs
Sponsor Trials
National Cancer Institute (NCI) 8
Children's Oncology Group 3
Bristol-Myers Squibb (BMS) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vincasar Pfs
Sponsor Trials
Other 13
NIH 8
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Fuji
Argus Health
Queensland Health
Fish and Richardson
Baxter
UBS
US Army
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.